299 related articles for article (PubMed ID: 12738676)
1. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Barker JN; Weisdorf DJ; DeFor TE; Blazar BR; Miller JS; Wagner JE
Blood; 2003 Sep; 102(5):1915-9. PubMed ID: 12738676
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
3. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
4. [The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Tang B; Zheng C; Liu H; Zhu X; Geng L; Wang X; Ding K; Yao W; Tong J; Song K; Zhang L; Qiang P; Zhang X; Sun Z
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):191-5. PubMed ID: 26926370
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.
Misawa M; Kai S; Okada M; Nakajima T; Nomura K; Wakae T; Toda A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Fujimori Y; Ogawa H; Hara H
Int J Hematol; 2006 Jan; 83(1):74-9. PubMed ID: 16443557
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
[TBL] [Abstract][Full Text] [Related]
7. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
Freyer CW; Babushok DV; Frey NV; Gill SI; Loren AW; Luger SM; Maity A; Martin ME; Plastaras JP; Porter DL; Hexner EO
Transplant Cell Ther; 2022 Sep; 28(9):590-596. PubMed ID: 35772699
[TBL] [Abstract][Full Text] [Related]
9. Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.
Kanda J; Rizzieri DA; Gasparetto C; Long GD; Chute JP; Sullivan KM; Morris A; Smith CA; Hogge DE; Nitta J; Song K; Niedzwiecki D; Chao NJ; Horwitz ME
Biol Blood Marrow Transplant; 2011 Jun; 17(6):867-74. PubMed ID: 20868761
[TBL] [Abstract][Full Text] [Related]
10. Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Abedin S; Peres E; Levine JE; Choi S; Yanik G; Couriel DR
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2062-6. PubMed ID: 25046834
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan.
Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Ghafoor T; Shamshad GU; Farhan M; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Satti HS; Anwer F; Ahmed P
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2375-2382. PubMed ID: 31394274
[TBL] [Abstract][Full Text] [Related]
13. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
Niederwieser D; Maris M; Shizuru JA; Petersdorf E; Hegenbart U; Sandmaier BM; Maloney DG; Storer B; Lange T; Chauncey T; Deininger M; Pönisch W; Anasetti C; Woolfrey A; Little MT; Blume KG; McSweeney PA; Storb RF
Blood; 2003 Feb; 101(4):1620-9. PubMed ID: 12393457
[TBL] [Abstract][Full Text] [Related]
14. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
Luznik L; Jalla S; Engstrom LW; Iannone R; Fuchs EJ
Blood; 2001 Dec; 98(12):3456-64. PubMed ID: 11719388
[TBL] [Abstract][Full Text] [Related]
15. [Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].
Bautista G; Regidor C; Gonzalo-Daganzo R; Cabrera JR
Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():47-51. PubMed ID: 21381288
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
17. Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.
Nakamae H; Storer BE; Storb R; Storek J; Chauncey TR; Pulsipher MA; Petersen FB; Wade JC; Maris MB; Bruno B; Panse J; Petersdorf E; Woolfrey A; Maloney DG; Sandmaier BM
Biol Blood Marrow Transplant; 2010 Mar; 16(3):384-94. PubMed ID: 19900571
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
Speziali C; Daly A; Abuhaleeqa M; Nitta J; Abou Mourad Y; Seftel MD; Paulson K
Leuk Lymphoma; 2019 Mar; 60(3):639-648. PubMed ID: 30160568
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
